The collaboration will see Shimadzu and UMG develop new clinical laboratory methods using LC-MS for TDM analysis.
Shimadzu, a laboratory instruments supplier, and University Medical Center Göttingen (UMG), announced a collaboration to develop new clinical laboratory methods. The focus of their research will be on using liquid chromatography-mass-spectrometry (LC-MS) for therapeutic drug monitoring (TDM) analysis. The collaboration is being performed under Shimadzu’s European Innovation Center program, which is designed to enable collaborations where outside experts can work with Shimadzu technologies.
According to a Oct. 27, 2022 press release, TDM tests, which measure the concentration of drugs currently in blood, have usually been done through an immunoassay, but LC-MS methods have recently grown in popularity due to advantages in strength and accuracy. However, complexity of sample preparation has prevented widespread adoption.
The collaboration will focus on developing Shimadzu's CLAM-2030, a fully automated sample preparation module for LC-MS. The device functions by placing blood collection tubes in position, wherein the module automatically performs sample pretreatment steps up to LC/MS/MS analysis. The collaboration aims to develop new methods for multiple target groups of drugs, as well as means of switching between these new methods easily and quickly.
Source: Shimadzu
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.